1. Search Result
Search Result
Results for "

ATP-sensitive K (KATP) channels

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15206
    Glibenclamide
    Maximum Cited Publications
    27 Publications Verification

    Glyburide

    Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Metabolic Disease
    Glibenclamide (Glyburide) is an orally active ATP-sensitive K + channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
    Glibenclamide
  • HY-B0341
    Nicorandil
    1 Publications Verification

    SG-75

    Potassium Channel Cardiovascular Disease
    Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
    Nicorandil
  • HY-136615

    Potassium Channel Neurological Disease
    5-Hydroxydecanoate sodium is a selective ATP-sensitive K + (KATP) channel blocker (IC50 of ~30 μM). 5-Hydroxydecanoate sodium is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has antioxidant activity .
    5-Hydroxydecanoate sodium
  • HY-B0254
    Glipizide
    2 Publications Verification

    CP 28720; K 4024

    Potassium Channel Metabolic Disease Cancer
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide
  • HY-108573
    P-1075
    1 Publications Verification

    Potassium Channel Cardiovascular Disease
    P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075
  • HY-14255
    Levcromakalim
    4 Publications Verification

    (-)-Cromakalim; BRL 38227

    Potassium Channel Cardiovascular Disease
    Levcromakalim ((-)-Cromakalim) is an ATP-sensitive K + channel (KATP) activator.
    Levcromakalim
  • HY-B0682A
    Mitiglinide calcium hydrate
    2 Publications Verification

    KAD-1229; S-21403

    Potassium Channel Metabolic Disease
    Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate
  • HY-17398
    Mitiglinide calcium
    2 Publications Verification

    KAD-1229 anhydrous; S21403 anhydrous

    Potassium Channel Metabolic Disease
    Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .
    Mitiglinide calcium
  • HY-15206S1

    Glyburide-d3

    Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Metabolic Disease
    Glyburide-d3 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].
    Glyburide-d3
  • HY-15206S

    Isotope-Labeled Compounds Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Metabolic Disease
    Glyburide-d11 is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
    Glyburide-d11
  • HY-14256
    BMS-191095
    1 Publications Verification

    Potassium Channel Cardiovascular Disease Neurological Disease
    BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .
    BMS-191095
  • HY-B0254S

    Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide-d11
  • HY-B0254R

    CP 28720 (Standard); K 4024 (Standard)

    Reference Standards Potassium Channel Metabolic Disease
    Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide (Standard)
  • HY-101069
    Y-26763
    2 Publications Verification

    Potassium Channel Cardiovascular Disease
    Y-26763 is a K + channel opener and active metabolite of Y-27152 . Y-26763 is an ATP-sensitive K + (KATP) channel activator .
    Y-26763
  • HY-B0341S

    Isotope-Labeled Compounds Potassium Channel Cardiovascular Disease
    Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
    Nicorandil-d4
  • HY-17451

    Potassium Channel Metabolic Disease
    Glibornuride is a blocker of ATP-sensitive K + channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride
  • HY-B0682

    KAD-1229 free acid anhydrous; S21403 free acid anhydrous

    Potassium Channel Metabolic Disease
    Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    Mitiglinide
  • HY-15206R

    Glyburide (Standard)

    Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Potassium Channel Reference Standards Metabolic Disease
    Glibenclamide (Standard) is the analytical standard of Glibenclamide. This product is intended for research and analytical applications. Glibenclamide (Glyburide) is an orally active ATP-sensitive K + channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
    Glibenclamide (Standard)
  • HY-17451R

    Reference Standards Potassium Channel Metabolic Disease
    Glibornuride (Standard) is the analytical standard of Glibornuride. This product is intended for research and analytical applications. Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride (Standard)
  • HY-119306

    Potassium Channel Cardiovascular Disease
    MCC-134, a blocker of mitochondrial and opener of surface ATP-sensitive K+ (KATP) channels, abrogates cardioprotective effects of chronic hypoxia. MCC-134 is a vasorelaxing agent .
    MCC-134
  • HY-117283

    rel-RP 52891

    Potassium Channel Others
    rel-Aprikalim (rel-RP 52891) is the relative configuration of Aprikalim (HY-121183). Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K + (KATP) channels in guinea pig ventricular myocytes .
    rel-Aprikalim
  • HY-B0341R

    SG-75 (Standard)

    Reference Standards Potassium Channel Cardiovascular Disease
    Nicorandil (Standard) is the analytical standard of Nicorandil. This product is intended for research and analytical applications. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
    Nicorandil (Standard)
  • HY-B0682S2

    Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    Mitiglinide-d5 calcium
  • HY-B0682S1

    Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    (2R)-Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .
    (2R)-Mitiglinide-d5 calcium
  • HY-17398R

    KAD-1229 anhydrous (Standard); S21403 anhydrous (Standard)

    Potassium Channel Reference Standards Metabolic Disease
    Mitiglinide (calcium) (Standard) is the analytical standard of Mitiglinide (calcium). This product is intended for research and analytical applications. Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .
    Mitiglinide calcium (Standard)
  • HY-B0682AR

    KAD-1229 (Standard); S-21403 (Standard)

    Reference Standards Potassium Channel Metabolic Disease
    Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate (Standard)
  • HY-121183

    RP 52891

    Potassium Channel Cardiovascular Disease
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .
    Aprikalim
  • HY-W777434

    Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Mitiglinide (calcium hydrate)-d8 is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide calcium hydrate-d8
  • HY-B0682S

    Potassium Channel Metabolic Disease
    Mitiglinide-d8 calcium hydrate (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .
    Mitiglinide-d8 calcium hydrate
  • HY-15206S2

    Glyburide-13C6

    Isotope-Labeled Compounds Autophagy Mitochondrial Metabolism Potassium Channel CFTR P-glycoprotein Metabolic Disease
    Glibenclamide- 13C6 (Glyburide- 13C6) is 13C labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K + channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
    Glibenclamide-13C6
  • HY-108573R

    Potassium Channel Cardiovascular Disease
    P-1075 (Standard) is the analytical standard of P-1075. This product is intended for research and analytical applications. P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075 (Standard)
  • HY-15026

    Endogenous Metabolite Inflammation/Immunology
    ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .
    ATB 429

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: